Conference Information

Welcome Message

Dear Colleagues and Friends,

The event Diabetes 2018 was very successful and I would like to thank everyone who are participated in making this event successful and for your support.

I wholeheartedly welcome you back to share your knowledge, experience and creative idea in this conference through interacting with worldwide experts from the field Diabetes, Cardiovascular, Pediatrics and Nutrition.

It is a great honour to have the opportunity to invite Diabetes Experts and Researchers, Academicians, Scientists, Industry Professionals and students and other affiliated individuals to the 3rd International Conference on Diabetes and Metabolism to be held in Frankfurt, Germany on November 29-30, 2019.

The conference includes keynote presentations, workshops, technical oral presentation, and poster presentations. By sharing research, participating in forums and collaborating with one another, your work will continue to impact the Diabetes field.

On behalf of the Organizing Committee of Diabetes 2019, we would like to express our warmest welcome to all of you who are participating in Diabetes 2019, and hope you will enjoy your stay in Frankfurt.

We look forward to seeing you in Frankfurt.

Regards
Diabetes 2019
Organizing Committee

About us

PULSUS Group Inc is proud to host the 3rd International Conference on Diabetes and Metabolism which will be held during November 29-30, 2019 in Frankfurt, Germany. The conference is themed around “Evincing the therapeutic approaches and development in Diabetes” with the aim to assemble a medical practitioner, a large audience of trade, healthcare, research, and to coach and produce a few fruitful speeches on the confined topics. This can be an excellent event to network, learn and have interaction with professionals within the field of Diabetes, Nutrition and Cardiovascular and Metabolic syndrome.

Benefits of Participation:

Diabetes Conference 2019 is open for Keynote talks, oral papers, poster shows and scientific panel discussions. We are targeting to inspire, discuss, and work along to bring out an answer for numerous issues related to Diabetes, Nutrition, and Cardiovascular and Metabolic syndrome.

The DIABETES 2019 gives a floor for the diabetologists, endocrinologists, Nutritionist, Dietician and experts both from Academia and Industry working in various subdomains of diabetes, endocrinology and metabolism. The Diabetes 2019 conference is an open call for all the Diabetes Doctors, Specialists, Endocrinologists, Researchers, Physicians, Business Analysts, Lab Technicia ns, Academicians, Nurses, Diabetes Educators, Nutritionists and Dieticians.

Opportunities for Conference Attendees

Specialists & Educators:

• Speaker Presentations

• Poster Display

• Symposium hosting

• Workshop organizing

Students & Research Scholars:

• Poster Competition

• Young Researcher Forum

• Student Attendee

• Group Registrations

Business Delegates:

• Speaker Presentations

• Symposium hosting

• Book Launch event

• Networking opportunities

• Audience participation

Universities, Associations & Societies:

• Association Partnering

• Collaboration proposals

• Academic Partnering

• Group Participation

Companies:

• Exhibitor and Vendor Booths

• Sponsorships opportunities

• Product launch

• Workshop organizing

• Scientific Partnering

• Marketing and Networking with clients

Important dates:

Conference Dates: November 29-30, 2019

October 20, 2019: Abstract submission deadline
November 28, 2019: Online registration system closes

Registration Benefits:

Both individual and group registrations are available

Only Registration:

Access to all scientific program sessions and plenary sessions
Access to exhibition hall and poster viewing area during opening hours
Handbook & Conference Kit
Certificate Accreditation by the International Organizing Committee Members (IOCM)
Abstracts will be published in the conference souvenir and respective international journal
Ask the Expert Forums (One to One Pre-Scheduled meeting on interest and availability)
10% abatement on the registration fees for the next annual conference
2 Coffee breaks (refreshments and snacks) during the conference
Lunch during the conference
Wi-Fi
Package A: Above 11 features including the following...

Breakfast during the Conference

2 Night’s accommodation (i.e. on November 29-30, 2019) in the deluxe single/double room at the conference venue

Package B: Above 13 features including the following...

1 Night extra accommodation i.e. on December 1, 2019(total 3 nights)

Discounts are available on Group Registrations

Diabetes 2019 registration customer service

Tel: +44 203 769 1778

Email: diabetesmeet@alliedforums.org

Sessions &Tracks

Session 1: Diabetes: Types and Complications

Diabetes is a major public health problem that is moving toward epidemic proportions comprehensively. Around the world, the predominance of chronic, non-communicable diseases is expanding at an alarming rate. Confusions from Diabetes, for example, coronary corridor and fringe vascular malady, stroke, diabetic neuropathy, removals, renal disappointment, and visual deficiency are bringing about expanding inability, diminished future and tremendous wellbeing costs for essentially every general public. Diabetes is sure to be a standout amongst the most difficult medical issues in the 21st century. In this session, we are focusing on the complexity of Diabetes.

Related Conferences: 3rd International Conference on Diabetes & Healthcare, March 18-19, 2019, Las Vegas, USA | 2nd Global Experts Meeting on Diabetes, Hypertension & Metabolic Syndrome, May 17-18, 2019, Singapore Atrium, Singapore | 2nd International Congress of Hypertension in Children and Adolescents, May 24-26, 2019, Warsaw, Poland | Diabetes and Endocrinology 2019 | 18th Global Conference on Diabetes & Nursing Care, June 27-28, 2019, Amsterdam, Netherlands | 28th European Diabetes Congress, July 17-18, 2019, Edinburgh, Scotland | 31st International Conference on Pediatrics & Adolescent Diabetes, August 12-13, 2019, Tokyo, Japan | 12th International Conference on Diabetes & Metabolism, September 18-19, 2019, San Francisco California, USA

Session 2: Genetics of Diabetics

Diabetes mellitus is a heterogeneous group of disorders described by persistent hyperglycemia. Type 1 and type 2 both are caused by a combination of genetic and environmental risk factors. In any case, there are other rare forms of diabetes that are directly inherited. These include maturity-onset diabetes and diabetes because of mutations in mitochondrial DNA. Within the following decade, the qualities that the genes that increase the risk of developing all forms of diabetes will likely be known. It is, in this way, important that researchers, wellbeing experts, health professionals, and members of the population at large consider how to maximize the advantages, and minimize the disadvantages of predictive genetic testing for diabetes.

Session 3: Nutrition & Diet

Nutrition and physical activity are essential parts of a healthy lifestyle when we have diabetes. Some foods raise blood glucose more than others. To deal with our blood glucose, we need to balance what we eat and drink with physical activity and diabetes medicine if we take any. In recent years, there has been much new proof evidence demonstrating the potentially preventable nature of type 2 diabetes, especially by the implementation of lifestyle measures such as weight control and exercise. In perspective on this and the devastating health impact of the disease, it seems prudent that primary prevention should be a major priority. This session, concentrating on nutritional intervention in the prevention of type 2 diabetes is used to make disease-specific recommendations.

Session 4: Insulin Medications

The objectives of this session are to reduce morbidity and to prevent complications. Medications that reduce insulin resistance include thiazolidinedione and biguanides, which have anti-hyperglycemic effects and insulin-sensitizing. Vast amounts of insulin are additionally utilized in overcoming insulin resistance. Reaction to the normal dose of insulin is seen in occurrences in which the resistance is due to enhanced destruction at the subcutaneous injection site. Antiobesity drugs, for example, orlistat, may reduce insulin resistance and related cardiovascular risk factors through weight reduction and other mechanisms.

Session 5: Diabetes and Skin complications

Diabetes can affect all aspects of the body, including the skin. Actually, such issues are sometimes the first sign that a person has diabetes. A variety of dermatologic indications have been connected with diabetes mellitus; these conditions fluctuate in seriousness and can be benign, deforming, and even life-threatening. Such skin changes can insight into patients’ glycemic control and might be the first sign of metabolic derangement in undiagnosed patients with diabetes. Recognition and management of these conditions are imperative in maximizing the quality of life and in avoiding serious adverse effects in patients with diabetes.

Session 6: Obesity complication and Management

Obesity is the main source of preventable disease and passing in the world. In recent years, the number of overweight people in industrialized countries has expanded, altogether, to such an extent that the World Health Organization (WHO) has considered obesity an epidemic. In the United States, 69% of grown-up populace is overweight or obese. In Canada, the self-reported data demonstrate that 20% of men and 17% of women are obese and 40% of men and 27% of women are overweight. People who are obese are at a lot higher hazard for serious medical conditions, for example, heart attack, high blood pressure, stroke, diabetes, gallbladder disease, and different cancers than people who have a healthy weight.

Session 7: Diabetes Podiatry

Due to the peripheral nerve dysfunction related to diabetes (diabetic neuropathy), patients have a reduced ability to feel torment. This implies minor wounds may remain undiscovered for quite a while. People with diabetes are likewise in danger of developing a diabetic foot ulcer. The research assesses that the lifetime occurrence of foot ulcers inside the diabetic community is around 15% and may move toward becoming as high as 25%. Those few patients are then 50% more likely to undergo another lower limb amputation. As such, diabetic foot care is one of the most essential parts of diabetes management and so we included this session at this wonderful gathering to discuss.

Session 8: Diabetes and Cardiovascular Diseases

Diabetes mellitus aggravates mechanisms underlying atherosclerosis and heart failure. Unfortunately, these mechanisms are not sufficiently modulated by therapeutic strategies focusing solely on optimal glycemic control with currently accessible drugs or approaches. Women with diabetes have a considerably more serious danger of coronary illness compared to those of similar age who don't have diabetes. Actually, cardiovascular disease is by a long shot the most frequent reason for death in the two people with diabetes. Lamentably, in patients with diabetes, improvement in survival after a heart attack has been not exactly half as much as in the overall population. The main objective of this conference is to build open attention to early discovery and better treatment of diabetes to prevent its complications.

Session 9: Diabetes and Cancer

People with diabetes are at higher risk for some, but not all, forms of cancer. The relationship between the two diseases is complex and surrounded by unanswered questions. Diabetes is associated with increased risk for some cancers (liver, pancreas, endometrium, colon and rectum, breast, bladder). Diabetes is associated with a reduced risk of prostate cancer. For some other cancer sites, there appears to be no association or the evidence is inconclusive. We hope this session to address some important questions about meaningful association between diabetes and cancer incidence or prognosis.

Session 10: Biomarkers and Diabetes

Biomarkers have an imperative impact in leading clinical trials and treating patients. Advances in molecular diagnostics help restorative experts make proficient, scientifically valid decisions. All the more efficient discovery and utilization of biomarkers in the development of anti-diabetes drugs will rely on accelerating our understanding of the pathogenesis of diabetes and explicitly its macrovascular complications. Procedural enhancements from different fields, particularly disease, are starting to demonstrate the route towards better models of diabetes pathogenesis and molecular biomarker discovery.

Session 11: Stem Cell Therapy for Diabetes

Stem cell therapy holds immense guarantee for the treatment of patients with diabetes mellitus. Research on the capacity of human embryonic stem cells to separate into islet cells has characterized the developmental stages and translation factors associated with this procedure. As a result, alternative forms of stem cell therapies, for example, umbilical cord stem cells, induced pluripotent stem cells and bone marrow-derived mesenchymal stem cells, have turned into an area of serious study. Recent advances in stem cell therapy may transform this into a realistic treatment for diabetes in the near future.

Session 12: Risk Factors and Related Diseases of Diabetes

Our chances of developing type 2 diabetes depend on a combination of risk factors such as our genes and lifestyle. Although we can’t change risk factors such as family history, age, or ethnicity, we can change lifestyle risk factors around eating, physical activity, and weight. These lifestyle changes can affect our chances of developing type 2 diabetes.

Session 13: Thyroid glands Disorders

The thyroid organ is prone to several very distinct problems, some of which are very common These issues can be separated into [1] the formation of nodules or lumps within the thyroid which are worrisome for the presence of thyroid cancer, [2] those concerning the production of hormone (too much, or too little) [3] those due to increased growth of the thyroid, causing compression of important neck structures or simply appearing as a mass in the neck, [4] those which are cancerous. Since the principle motivation behind thyroid hormone is to "run the body's metabolism," it is justifiable that individuals with this condition will have indications related to slow metabolism.

Session 14: Nanotechnology in Diabetes

Nanotechnology in diabetes investigate has encouraged the advancement of novel glucose estimation and insulin delivery modalities which hold the possibility to drastically improve quality of life for diabetics. Current advancement in the field of diabetes explore at its interface with nanotechnology is our centre of attention. Specifically, we look at glucose sensors with nanoscale components including metal nanoparticles and carbon nanostructures. A portion of the applications of nanotechnology in treating diabetes mellitus are artificial pancreas, rather than pancreas transplantation utilization of artificial beta cells, for the oral conveyance of insulin use of nanospheres as biodegradable polymeric carriers and so on. In this session, the utilization of nanotechnology in treating diabetes mellitus will be discussing.

Session 15: Herbal Therapy for Diabetes

There are heaps of chemical agents accessible to control and to treat diabetic patients, yet all-out recovery from diabetes has not been reported for up to this date. An alternative to these manufactured operators, synthetic agents, plants provides potential sources of hypoglycemic drugs are generally utilized in several traditional systems of medicine to prevent diabetes. A few medicinal plants have been researched for their medicinal use in various types of diabetes and have shown up in various scientific journals. The impacts of these plants may delay the advancement of diabetic difficulties and correct the metabolic irregularities using an abnormality using a variety of mechanisms. An impressive number of plants were exposed to clinical trials and were discovered effective. In addition, during the past few years, numerous phytoconstituents in charge of antidiabetic impacts have been separated from hypoglycaemic plants.

Session 16: Endocrinology and Metabolism

The endocrine issue is consistently astounding, including a mixed picture of hyposecretion and hypersecretion because of the information parts related to the endocrine system. For example, most kinds of hyperthyroidism are connected with an excess of thyroid hormone and a low dimension of thyroid animating hormone. Patients with multi-transfused thalassemia major may make serious endocrine complexities because of iron overload. Syndrome X is a term that is much of the time associated with the dissipates that exist together in various people with different sorts of cardiovascular disease (CVD) and furthermore diabetes in association with insulin resistance, hyperinsulinemia and cell ionic abnormality.

Session 17: General Pediatrics

Type 1 diabetes is a constant disease described by the body's inability to produce insulin because of the auto-immune system demolition of the beta cells in the pancreas. Most pediatric patients with diabetes have type 1 and a lifetime reliance on exogenous insulin. This observable underneath portrays the impacts of insulin lack. Dietary nutrient D supplementation is related to reduce the danger of type 1 diabetes. Ensuring sufficient nutrient D supplementation for infants could turn around the trend in the incidence of type 1 diabetes. The goal of this session in type 1 diabetes is to avoid the acute and chronic complications of the disease.

Session 18: Gynecologic Endocrinology and Infertility

Diabetes type 1 and type 2 ought to be considered in the differential diagnosis of menstrual abnormalities and infertility. Reproductive period of diabetic ladies might be decreased because of delayed menarche and premature menopause. During the reproductive years, diabetes has been related to menstrual abnormalities, for example, secondary amenorrhea and oligomenorrhea. Ladies with persistent menstrual abnormalities in spite of sufficient treatment need to be approached by broader evaluation, which will incorporate the examination of the hypothalamic– pituitary– ovarian axis and the hormonal status, anti-ovarian autoantibodies, presence of autoimmune thyroid disease and hyperandrogenism.

Session 19: Neuro Endocrinology

The central neuroendocrine systems serve in as an interface between the brain and a significant number of the peripheral endocrine systems. A neuroendocrine system can be characterized as the glands and non-endocrine tissues, arrangements neurons and hormones, the neurochemicals and humoral signs they produce and receive, that work in a coordinated manner to collectively regulate a physiological or behavioural state. In this session, we define and describe different types of neuroendocrine systems, and review the basic integrative mechanisms that each people to operate under normal physiological circumstances.

Session 20: Advanced Technologies for the Treatment of Diabetes

Contribution from continuous glucose monitors (CGMs) is a basic component of artificial pancreas (AP) frameworks, however, CGM execution issues keep on restricting advancement in AP research. While G4 PLATINUM has been incorporated into AP frameworks around the globe and used in numerous successful AP controller possibility studies, this system was intended to address the needs of overall CGM users as an adjunctive use system. This session explicitly addresses the heightened performance requirements for future AP studies.

Session 21: Business and Economics of Diabetic Products

Diabetes is a global disease. The field of diabetes innovation to advance and in order for diabetes products containing novel advancements to be developed and used, these items will need to survive economically. Financial conditions and approaches of national different administrative bodies that control access to therapeutic advances must be positive in order for a patient in that country to have access to technology, and these arrangements are frequently extraordinary in every nation. Approximately 250 million people affected by diabetes around the world, diabetes is extracting an expanding toll from the world economy. People with diabetes acquire medical costs that are a few times higher than those without diabetes. Moreover, diabetes prompts critical aberrant expenses to the economy through early retirement and a disproportionate requirement for sick days and disability. As the U.S. populace becomes more established and fatter, it may be foreseen that diabetes predominance rates and future expenses of this sickness may develop at much quicker rates than would be extrapolated from current prevalence rates.

Market Analysis

Diabetes has progressively turned into a way of lifestyle-related disease as it besets youthful and old. As the numbers of patients develop over the globe, there has never been a more powerful and urgent need for novel therapeutic measures in a clinical and preclinical assessment that arrest the development of the disease. The worldwide market value for diabetes treatments and diagnostics has come to $48.5 billion. The largest section of the market, insulin products, is worth $20.8 billion in the present occasions, including administration and diagnostic devices. Monitoring devices and other related apparatus, the second-largest market is built up with an investment of $13.5 billion in which was proposed for $11.3. The speediest growing section of oral diabetic entanglement of hypoglycemia drugs producing financing is $14.13 in the present situation of diabetes showcase.

In Europe:

Europe diabetes spending is 9% of complete healthcare expenditure, spending on diabetes to a great extent shift among nations in Europe. It ranges from 312 Euro for each Capita in the Republic of Macedonia to 6,896 Euros for each Capita in Norway. Likewise, the Prevalence has mostly differed across Europe ranging from 2.8% in Albania to 9.8% in Portugal. In cost effective countries, diabetes is one of the leading causes of blindness, cardiovascular disease, lower limb amputation and kidney failure.

Diabetes Drug Market:

European Diabetes Drug Market is required to develop with a high CAGR of 6.2% in the forecast period because of the Increasing prevalence of diabetes, an unhealthy diet, a routine increment in the geriatric populace and physical inactivity. Diabetes is an increasingly common health condition which leads to disabling and potentially fatal health complications

According to journal Diabetic Medicine, the yearly spending by NHS on Diabetes in the United Kingdom will increment from 9.8 billion GBP to 16.9 GBP £ in 2035, it is expected that 17 per cent of the whole NHS budget will be spending on diabetes.

Visa Assistance

Diabetes 2019 will be happy to help you in all ways to plan your trip to Frankfurt, Germany.We will be happy to help you with the official invitation letter for the approval of your VISA.

Mail us at: diabetes@pulsusseries.com

When applying for a visa to Europe you will have to submit some required documents as part of the Schengen Visa Application.The following list of documents is required for any short-term Schengen visa application:

Visa application form. Fully completed and signed.
Two recently taken photos must be attached. Both photos must be taken within the last three months, according to the visa photo requirements.

A valid passport. Not older than 10 years and it should valid for at least three more months beyond the date you plan to leave Schengen area. Older passports with visas on them (if you have any).
Round trip reservation or itinerary. It must include dates and flight numbers specifying entry and exit from the Schengen area. You can use the visa consultation services. These guys can handle most of your visa requirements such as flight itineraries, hotel reservations along with free consultation over email.
Travel insurance policy. A document that proves you have travel health insurance for the whole Schengen territory, with a minimum coverage of 30,000 euros in case of any medical emergency as illnesses, accidents and even repatriation in case of death.

Proof of accommodation. A document that shows where you will be accommodated throughout your stay in Schengen. This can be one of the following: